logo-loader
Kazia Therapeutics Ltd

Kazia Therapeutics gains new substantial holder in The Bank of New York Mellon

The company plans to begin recruitment for its upcoming dose expansion cohort immediately.

1557291739_shutterstock_1024946599.jpg
Kazia’s shares last traded at 44 cents each

Kazia Therapeautics Limited (ASX:KZA) has a new substantial holder in The Bank of New York Mellon Corporation (NYSE:BK) which recently staked a 27.09% interest.

The world’s largest custodian bank now holds a total of 16,840,686 securities in the Australian oncology-focused biotech company.

 

 

Kazia Therapeutics chief executive officer James Garner said the superior results from the ongoing study of GDC-0084 in newly-diagnosed glioblastoma patients was an important milestone for the company.

He added the current, second stage of the two-part study (which began in September) will transition into observing more patients, with higher doses of the drug.

READ: Kazia Therapeautics’ ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients

Garner continued: “One of the exciting things about our drug GDC-0084 is that its designed to cross the blood-brain barrier.

“We are focusing on newly-diagnosed patients in earlier stages of the disease and we think we can offer a much bigger benefit there.”

The company confirmed a higher maximum tolerated dose (MTD) of 60 milligrams in new safety data from its ongoing phase-IIa clinical study earlier this week.

Quick facts: Kazia Therapeutics Ltd

Price: $0.55

Market: ASX
Market Cap: $34.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kazia Therapeutics releases new safety data to assist in brain cancer treatments

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer James Garner speaks to Proactive Investors about new safety and tolerability data from the company's phase-IIa clinical trial of brain cancer treatment.    Garner said the superior results from the ongoing study of...

on 7/5/19

2 min read